| pubmed-article:10755201 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10755201 | lifeskim:mentions | umls-concept:C0035173 | lld:lifeskim |
| pubmed-article:10755201 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:10755201 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:10755201 | lifeskim:mentions | umls-concept:C0005839 | lld:lifeskim |
| pubmed-article:10755201 | lifeskim:mentions | umls-concept:C0003009 | lld:lifeskim |
| pubmed-article:10755201 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:10755201 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:10755201 | lifeskim:mentions | umls-concept:C0599724 | lld:lifeskim |
| pubmed-article:10755201 | lifeskim:mentions | umls-concept:C0023981 | lld:lifeskim |
| pubmed-article:10755201 | lifeskim:mentions | umls-concept:C1522492 | lld:lifeskim |
| pubmed-article:10755201 | lifeskim:mentions | umls-concept:C1958507 | lld:lifeskim |
| pubmed-article:10755201 | lifeskim:mentions | umls-concept:C0205191 | lld:lifeskim |
| pubmed-article:10755201 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:10755201 | pubmed:dateCreated | 2000-8-11 | lld:pubmed |
| pubmed-article:10755201 | pubmed:abstractText | The QUO VADIS (the effects of QUinapril On Vascular Ace and Determinants of ISchemia) study was a randomized, double-blind, placebo-controlled trial designed to evaluate the effects of long-term angiotensin-converting enzyme (ACE) inhibition on angiotensin II formation in human vasculature. Patients (n = 187) scheduled for coronary artery bypass surgery used study medication 27 +/- 1 days before surgery. Segments of internal mammary arteries were exposed to increasing doses (0.1 nM-1 microM) of angiotensin I and II in organ baths. The rate of local angiotensin II formation is a function of the reciprocal of the difference between the pEC50's of the dose response curves to angiotensin I and II (-log/mol) and of the area between the curves (units). Quinapril (40 mg) and captopril (3 x 50 mg) similarly and significantly reduced mean blood pressure compared with placebo (p = 0.04). Difference between pEC50's was 0.90 +/- 0.08 in quinapril patients compared with 0.60 +/- 0.08 for placebo (p = 0.01); the area between curves was 91 +/- 8 for quinapril patients compared with 67 +/- 8 for placebo (p = 0.03). Angiotensin II formation was decreased to a lesser extent with captopril and was not statistically different from placebo (p = 0.3); the difference between pEC50's was 0.83 +/- 0.15; the area between curves was 84 +/- 12. This is the first randomized study to demonstrate that long-term oral treatment with an ACE inhibitor reduces vascular angiotensin II formation in humans. | lld:pubmed |
| pubmed-article:10755201 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10755201 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10755201 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10755201 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10755201 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10755201 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10755201 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10755201 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:10755201 | pubmed:issn | 0920-3206 | lld:pubmed |
| pubmed-article:10755201 | pubmed:author | pubmed-author:EbelsTT | lld:pubmed |
| pubmed-article:10755201 | pubmed:author | pubmed-author:KingmaJ HJH | lld:pubmed |
| pubmed-article:10755201 | pubmed:author | pubmed-author:van GilstW... | lld:pubmed |
| pubmed-article:10755201 | pubmed:author | pubmed-author:CrijnsH JHJ | lld:pubmed |
| pubmed-article:10755201 | pubmed:author | pubmed-author:BuikemaHH | lld:pubmed |
| pubmed-article:10755201 | pubmed:author | pubmed-author:MorshuisW JWJ | lld:pubmed |
| pubmed-article:10755201 | pubmed:author | pubmed-author:PintoY MYM | lld:pubmed |
| pubmed-article:10755201 | pubmed:author | pubmed-author:HaberH EHE | lld:pubmed |
| pubmed-article:10755201 | pubmed:author | pubmed-author:VoorsA AAA | lld:pubmed |
| pubmed-article:10755201 | pubmed:author | pubmed-author:OostergaMM | lld:pubmed |
| pubmed-article:10755201 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10755201 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:10755201 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10755201 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10755201 | pubmed:pagination | 55-60 | lld:pubmed |
| pubmed-article:10755201 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10755201 | pubmed:meshHeading | pubmed-meshheading:10755201... | lld:pubmed |
| pubmed-article:10755201 | pubmed:meshHeading | pubmed-meshheading:10755201... | lld:pubmed |
| pubmed-article:10755201 | pubmed:meshHeading | pubmed-meshheading:10755201... | lld:pubmed |
| pubmed-article:10755201 | pubmed:meshHeading | pubmed-meshheading:10755201... | lld:pubmed |
| pubmed-article:10755201 | pubmed:meshHeading | pubmed-meshheading:10755201... | lld:pubmed |
| pubmed-article:10755201 | pubmed:meshHeading | pubmed-meshheading:10755201... | lld:pubmed |
| pubmed-article:10755201 | pubmed:meshHeading | pubmed-meshheading:10755201... | lld:pubmed |
| pubmed-article:10755201 | pubmed:meshHeading | pubmed-meshheading:10755201... | lld:pubmed |
| pubmed-article:10755201 | pubmed:meshHeading | pubmed-meshheading:10755201... | lld:pubmed |
| pubmed-article:10755201 | pubmed:meshHeading | pubmed-meshheading:10755201... | lld:pubmed |
| pubmed-article:10755201 | pubmed:meshHeading | pubmed-meshheading:10755201... | lld:pubmed |
| pubmed-article:10755201 | pubmed:meshHeading | pubmed-meshheading:10755201... | lld:pubmed |
| pubmed-article:10755201 | pubmed:meshHeading | pubmed-meshheading:10755201... | lld:pubmed |
| pubmed-article:10755201 | pubmed:meshHeading | pubmed-meshheading:10755201... | lld:pubmed |
| pubmed-article:10755201 | pubmed:meshHeading | pubmed-meshheading:10755201... | lld:pubmed |
| pubmed-article:10755201 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10755201 | pubmed:articleTitle | Angiotensin II formation in human vasculature after chronic ACE inhibition: a prospective, randomized, placebo-controlled study. QUO VADIS Investigators. | lld:pubmed |
| pubmed-article:10755201 | pubmed:affiliation | Department of Clinical Pharmacology, University of Groningen, The Netherlands. | lld:pubmed |
| pubmed-article:10755201 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10755201 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10755201 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:10755201 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10755201 | lld:pubmed |
